Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies
ConclusionDM does not seem to affect overall or progression-free survival of mCRC patients treated with first-line FOLFOX chemotherapy. Moreover, DM does not influence the incidence or severity of oxaliplatin-induced paresthesia in those patients while it might lead to a shorter time to develop oxaliplatin-induced paresthesia compared to non-diabetic patients.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Diabetes | Diabetes Mellitus | Eloxatin | Endocrinology | Fortamet | Laryngeal Cancer | Metformin | Neurology | Pain | Study